Loading stock data…
PRAX
$329.81-7.79 (-2.31%)
Market OpenUpdated 11:41 AM EDT
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Praxis Precision Medicines, Inc. in the Healthcare sector is trading at $337.61. The stock is currently near its 52-week high of $356.00, remaining 65.4% above its 200-day moving average. Technical signals show neutral RSI of 48 and bearish MACD signal, explaining why PRAX maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 48) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$329.81
Potential Upside
5%
Whystock Fair Value$346.31
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus17 analysts
Mean target$634.65+92.4%
Range$130.00 – $1245
Fundamentals
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The compa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.39B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.97
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-28.58%
Volume
Today's trading volume
163,803
Recent News
Praxis (PRAX) Aligns Pay With Ulixacaltamide Progress Is Incentive Design Now a Key Edge?
Praxis Precision Medicines, Inc. has already called its 2026 virtual annual meeting for June 10 to vote on director elections, auditor ratification, and an advisory Say-on-Pay proposal, following past-year progress such as positive Phase 3 ulixacaltamide data in essential tremor and an early new drug application filing. The company is pairing these clinical and regulatory advances with performance-based restricted stock units and has attracted a more than 5% passive stake from Vanguard...
A Look At Praxis Precision Medicines (PRAX) Valuation After Strong Long Term Shareholder Returns
Why Praxis Precision Medicines is on investors’ radar Praxis Precision Medicines (PRAX) has drawn attention after recent trading left the stock at a last close of $324.20, against a backdrop of mixed short term returns and a longer track record in development stage CNS therapies. See our latest analysis for Praxis Precision Medicines. Recent trading reflects that momentum has cooled after very strong long term gains, with a 1 day share price return of 1.68% and a 1 year total shareholder...
Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide
Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 10 best biotech stocks with highest upside potential. As of the close of play on April 24, the broader consensus sentiments towards Praxis Precision Medicines Inc. (NASDAQ:PRAX) remained strongly bullish. The stock received coverage from 16 analysts, 14 of whom assigned Buy ratings and 1 gave […]
Praxis Precision Medicines Inc. (PRAX): Rare Triple-Catalyst Setup in Neurology
We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Praxis Precision Medicines, Inc. (NASDAQ:PRAX) ranks 1st on this list. Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is still pre-revenue but Wall Street is piling into the stock because of a rare triple-catalyst setup in neurology. There are two major regulatory decisions […]
Praxis Precision Medicines (PRAX): One of the Best Upside Stocks
Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 9 Best Upside Stocks to Buy According to Analysts. Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the best upside stocks to buy according to analysts. On April 14, Praxis Precision Medicines announced that the US FDA accepted its NDA for ulixacaltamide HCl. This treatment is […]